EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum leucine-rich α-2-glycoprotein and monocyte chemoattractant protein-1 as novel biomarkers for predicting vedolizumab response in patients with ulcerative colitis

Takeo Yoshihara iD, Shinichiro Shinzaki iD, Tetsuji Naka, Hideki Iijima iD, Yoshito Hayashi iD, OGF study group, Kaori Ishiguro, Yuji Baba, Tetsuo Takehara iD, OGF study group

Crohn’s & Colitis 360 · 08.07.2026 · 8 (3)

DOI: 10.1093/crocol/otag084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Crohn’s & Colitis 360, online erschienen am 11.08.2026. Verfasst von Takeo Yoshihara und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, The University of Osaka, Graduate School of Medicine, Osaka 565-0871, Japan. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company Limited, Envision Ignite, an Envision Medical Communications agency, Envision Pharma Group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Effective, minimally invasive biomarkers are needed to predict treatment outcomes in ulcerative colitis (UC). This multicenter observational study investigated predictive serum and genetic biomarkers for vedolizumab (VDZ) therapy in UC, including serum leucine-rich α-2-glycoprotein (LRG), cytokines, and differentially expressed genes (DEGs) in intestinal tissue.

Methods

Eligible patients (18-80 years; moderately to severely active UC) received intravenous VDZ (300 mg; Weeks 0, 2, 6, then every 8 weeks through Week 54). Serum biomarkers were compared between those who did/did not achieve clinical remission (CR; full Mayo score ≤2, all subscores ≤1) or mucosal healing (MH; Mayo endoscopic subscore ≤1) at Week 14. Week 0 inflammatory tissue data were stratified by Week 14 VDZ effect (CR and complete-MH [Mayo endoscopic subscore = 0]) for DEGs.

Results

Overall, 21 patients were included. Mean serum LRG was significantly lower in the CR (n = 11) versus non-CR (n = 10) group at Week 0 (19.0 vs 29.0 µg/mL; P = .0267) and Week 6 (13.4 vs 19.6 µg/mL; P = .0340), and in the MH (n = 14) versus non-MH (n = 7) group at Week 6 (13.7 vs 21.6 µg/mL; P = .0326). Mean monocyte chemoattractant protein-1 (MCP-1) was significantly different between CR and non-CR groups at Week 0 (609.0 vs 403.4 pg/mL; P = .0018) and MH versus non-MH at Week 0 (587.2 vs 358.9 pg/mL; P < .001) and Week 6 (606.9 vs 451.6 pg/mL; P = .037). No significant differences in C-reactive protein and fecal calprotectin levels were observed. DEGs included LRG1, LRG-related cytokines, and MCP1.

Conclusions

Serum LRG and MCP-1 may be candidate biomarkers of VDZ treatment response in UC.

Schlagwörter

Stichwörter der Autor:innen

colitisinflammatory bowel diseaseleucine-rich α-2-glycoproteinulcerative

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, The University of Osaka, Graduate School of Medicine, Osaka 565-0871, Japan.
  • Department of Gastroenterology, Hyogo Medical University School of Medicine, Hyogo 663-8501, Japan.
  • Institute for Biomedical Sciences Molecular Pathophysiology, Iwate Medical University, Iwate 028-3694, Japan.
  • Division of Allergy and Rheumatology, Department of Internal Medicine, School of Medicine Iwate Medical University, Iwate 028-3695, Japan.
  • Osaka International Medical & Science Center, Osaka Keisatsu Hospital, Osaka 543-0042, Japan.
  • Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo 103-8668, Japan.

ORCID-Profile: Takeo Yoshihara, Shinichiro Shinzaki, Hideki Iijima, Yoshito Hayashi, Tetsuo Takehara

Förderung

  • Takeda Pharmaceutical Company Limited
  • Envision Ignite, an Envision Medical Communications agency
  • Envision Pharma Group
  • Takeda

Zitieren

APA

Yoshihara, T., Shinzaki, S., Naka, T., Iijima, H., Hayashi, Y., OGF study group, Ishiguro, K., Baba, Y., Takehara, T., & OGF study group (2026). Serum leucine-rich α-2-glycoprotein and monocyte chemoattractant protein-1 as novel biomarkers for predicting vedolizumab response in patients with ulcerative colitis. Crohn’s & Colitis 360, 8(3). https://doi.org/10.1093/crocol/otag084

Vancouver

Yoshihara T, Shinzaki S, Naka T, Iijima H, Hayashi Y, OGF study group, et al. Serum leucine-rich α-2-glycoprotein and monocyte chemoattractant protein-1 as novel biomarkers for predicting vedolizumab response in patients with ulcerative colitis. Crohn’s & Colitis 360. 2026;8(3). doi:10.1093/crocol/otag084

BibTeX
@article{Yoshihara2026,
  author = {Yoshihara, Takeo and Shinzaki, Shinichiro and Naka, Tetsuji and Iijima, Hideki and Hayashi, Yoshito and OGF study group, OGF study group and Ishiguro, Kaori and Baba, Yuji and Takehara, Tetsuo and OGF study group, OGF study group},
  title = {Serum leucine-rich α-2-glycoprotein and monocyte chemoattractant protein-1 as novel biomarkers for predicting vedolizumab response in patients with ulcerative colitis},
  journal = {Crohn’s & Colitis 360},
  year = {2026},
  volume = {8},
  number = {3},
  doi = {10.1093/crocol/otag084}
}
Kostenlos starten →